Tortugas Neuroscience Raises $106M in Seed and Series A Funding

The company plans to use the funds to support its research and development, including completing Phase 2 clinical trials for its two main candidates and developing new medicines using proven approaches for large, well-defined conditions.

Licensed from Eisai Co., Ltd. (Tokyo, Japan) and Jiangsu Hansoh Pharmaceutical Group Ltd., the company’s clinical-stage pipeline includes potential treatments for schizophrenia, tinnitus, focal epilepsy, reversible encephalopathies, and other serious central nervous system conditions. These programs use small-molecule compounds with proven mechanisms of action, and Tortugas aims to develop them as once-daily oral medicines with unique benefits and potential for use in multiple conditions.

Tortugas is led by experienced drug developers and biotech leaders, CEO Jeff Jonas, M.D., and President and Head of R&D Al Robichaud, Ph.D., both formerly of Sage Therapeutics. The company focuses on developing medicines with clear approval pathways and benefits that can make a meaningful difference in patients’ lives.

Read More:Reliable Robotics Raises $160M in Funding

"We believe each of our programs is well-positioned for differentiation in the marketplace," said Jeff Jonas, M.D., CEO of Tortugas Neuroscience. "Tortugas curated its pipeline for innovative therapeutics that have high potential for clinical differentiation and for reaching their target patient markets. I am confident that with our team’s demonstrated drug development capabilities, we will deliver on our promise to patients in need.”

"We are driven to improve treatment options for patients suffering from CNS disorders," said Al Robichaud President Head of Research & Development at Tortugas. "The unmet patient need is indeed immense and we are deeply appreciative of this financial support to help us achieve our goals.”

About Tortugas Neuroscience

Tortugas Neuroscience is a biotech company focused on brain diseases and the development of effective medicines. It uses proven approaches, and faster development paths to create treatments that can make a real difference for patients around the world.

About Cure Ventures

Founded in 2021 Cure Ventures is a life sciences venture capital firm that focuses on building new companies around breakthrough curative technologies. The team values both people and science, and is led by experienced industry experts. Its approach is based on three main ideas: using seed funding to reduce risk and support early success, focusing on genetically validated science to improve outcomes, and working closely with founders through in house operators to guide daily decisions and growth.

Read More:Syenta Raises $26M in Series A Funding Led by Playground Global